NCT02944864View on ClinicalTrials.gov

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

PHASE1TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

May 23, 2021

Study Completion Date

September 15, 2022

Conditions
Advanced Cancer
Interventions
DRUG

TQ-B3395

TQ-B3395 p.o. qd

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY